A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors

Inclusion Criteria: Dose escalation phase (cohort A1 and A2) 1. Male or female subjects age ≥ 18 years 2. Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors (excluding lymphoma) , unresponsive to standard treatment or for whom no standard treatment is available or appropriate 3. ECOG performance status 0 or 1 4. Adequate bone marrow, renal, hepatic at screening and at Baseline 5. Subject must have measurable diseases as per RECIST v1.1 criteria Exclusion Criteria: 1. Symptomatic brain metastases, CNS tumors 2. Symptomatic motor or sensory peripheral neuropathy (≥ grade 2) 3. Subjects having ophthalmologic abnormalities 4. Active serious systemic disease (infection,organic or dysmetabolic desease) 5. Left ventricular ejection fraction (LVEF) \< 45% as determined by MUGA scan or echography at screening 6. QTc \> 470 msec on screening ECG or congenital long QT syndrome 7. Biologic therapy (including ADCs ≤ 4 weeks before first study treatment administration)